Investing
Bristol-Myers Squibb to acquire Karuna for $14 billion – WSJ
© Reuters. Bristol-Myers Squibb (BMY) to acquire Karuna (KRTX) for $14 billion – WSJ
Bristol Myers Squibb (NYSE:) has reportedly agreed to a deal to acquire neuroscience-drug developer Karuna Therapeutics (NASDAQ:) for $14 billion.
Under the terms of the agreement, Bristol Myers Squibb will pay $330 per share in cash for Karuna, which includes $1.3 billion in cash that Karuna currently holds, according to the Wall Street Journal.
BMY shares fell 2.2% in pre-market on this news. Karuna shares closed at $215.19, which means BMY agreed to pay a premium of over 50%.
The deal, expected to close in the first half of the next year, is a strategic move by Bristol Myers Squibb to strengthen its presence in the psychiatric and neurological drugs market.
The centerpiece of Karuna’s portfolio is an experimental drug called KarXT, currently under review by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
Read the full article here
-
Side Hustles6 days ago
How to Develop Empowered Leaders Within Your Own Team
-
Passive Income5 days ago
Are You Running Your Business, or Is Your Business Running You?
-
Side Hustles4 days ago
How to Be Unapologetically You and Why It Matters
-
Investing5 days ago
7 Marketing Strategies to Help Your Startup Grow and Scale
-
Side Hustles5 days ago
How Your Body Language Can Help Win a Disagreement
-
Side Hustles5 days ago
OpenAI Raises Record $6.6 Billion, Adds 50 Million New Users
-
Side Hustles6 days ago
Why the Best Time to Sell Your Business Is When You Least Expect It
-
Passive Income4 days ago
How AI-Driven Personalization Is Transforming the Retail Industry